Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2018
At a glance
- Drugs Itacitinib (Primary) ; Dabrafenib; Trametinib
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 06 Mar 2018 Planned initiation date changed from 30 Sep 2017 to 30 Jul 2018.
- 07 Sep 2017 New trial record